Fulcrum Therapeutics Inc

$7.90 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on improving the lives of patients with genetically defined rare diseases. The Company has developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The Company is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders. The Company uses its proprietary product engine to identify and validate drug targets and develop product candidates to address diseases caused by the mis-expression of certain genes. Its product candidate includes losmapimod, is a small molecule that is developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, is a small molecule designed to bind embryonic ectoderm development (EED).

Stock Analysis

last close $8.53
1-mo return 65%
3-mo return 0.4%
avg daily vol. 606.02T
52-week high 33.1
52-week low 3.21
market cap. $345M
forward pe -
annual div. -
roe -76.7%
ltg forecast -
dividend yield -
annual rev. $14M
inst own. 98.2%
baraka

Subscribe now for daily local and international financial news

Subscribe